Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models.

Latta-Mahieu, Martine

Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models. [electronic resource] - Glia 03 2018 - 492-504 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1098-1136

10.1002/glia.23260 doi


Alzheimer Disease--immunology
Amyloid beta-Peptides--genetics
Animals
Antibodies--administration & dosage
Brain--immunology
Disease Models, Animal
Female
Humans
Immunohistochemistry
Immunotherapy
Interferon-gamma--blood
Male
Mice, Inbred C57BL
Mice, Transgenic
Presenilin-1--genetics
Programmed Cell Death 1 Receptor--immunology
RNA, Messenger--metabolism
Random Allocation
Spleen--immunology